The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Don't think any of the big players will be interested. The only piece they would want is the super duper disruptive Ranger technology. Lol
Can anyone remind me of the ye 24 forecast revenue.
Andrewkennedy079@gmail.com
Hemo, there's plenty of time yet for another bidder. Hopefully DD going on as we speak..lol
Mt500, have you got behind Andyken yet? That's the best way. Can't see the point of losing any more and voting against.
Captain, who knows, but both sets of management seem as bad as each other. At least ygen has 20+% annual growth and likely much more with the ££££ Ncyt can put into it.
They will likely cull quite a few more bods too, which will obviously help matters.
Hemo, it will be done and dusted before ygen runs out of cash. Not sure it's better to vote against though. Another suitor is the only way this situation will improve. I will vote for Andyken.
Growth of over 20% and all to market expectations. Have you seen Ncyt update?
Kaeren, Ncyt will already have a slice, and this will only get better, especially if/ when the Ranger technology gets more traction. It was only soft launched last year and it's already pulling in multi millions. I'm sure you'll hear the term "size selection" plenty more when you take over.